Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Disappointing study results for Cytokinetics By: MarketMinute.com Stock News November 21, 2017 at 18:26 PM EST Cytokinetics Inc. (Nasdaq: CYTK) reported disappointing results from a Phase 3 clinical trial of tirasemtiv to treat patients with amyotrophic lateral sclerosis. Shares of the biopharmaceutical plunged $2.85 to close at $8.25. Related Stocks: Cytokinetics Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Disappointing study results for Cytokinetics By: MarketMinute.com Stock News November 21, 2017 at 18:26 PM EST Cytokinetics Inc. (Nasdaq: CYTK) reported disappointing results from a Phase 3 clinical trial of tirasemtiv to treat patients with amyotrophic lateral sclerosis. Shares of the biopharmaceutical plunged $2.85 to close at $8.25. Related Stocks: Cytokinetics